Redeye comments on Heliospectra’s proposed SEK49.5m rights issue, partly secured by main shareholder...
* Q3'25 numbers due on 5 November at 07:45 CET * Adj.
* We forecast 7% EBITA growth in Q3'25 * M&A could add 30-40% to '27e EBITA * We raise our fair valu...
Redeye comments on Invisio’s announcement of a 10-year contract with US Coast Guard regarding wirele...
The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserv...
Redeye leaves Addnode’s CMD with a positive impression, as the company’s ambition for growth and mar...
Redeye provides a brief comment on Scibase receiving an initial order valued at approximately SEK8m ...
Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue ...
Redeye believes the data is solid and in line with previous readouts.
Bioteknikbolaget Aptahem, som utvecklar läkemedelskandidaten Apta-1 mot sepsis, har tagit ett strate...
Redeye comments on the directed share issue in which Sivers Semiconductors raised SEK95m before tran...
Atria announced today its TOGETHER 2030 strategy for 2025-30 with refined financial targets.
We initiate coverage of YIT with a REDUCE-rating and TP of EUR 3.
Redeye is positive on Senzime’s recent news flow, with contracts from important US hospitals.
Redeye comments on Verve's announced acquisition. The company is acquiring Acardo Group for EUR24.
